


MRI Safety Information Card



The INLEXZO carton includes an MRI Safety Card. If you need an additional card, print out this copy of the MRI Safety Information Card, complete the details and give it to the patient. Advise the patient to carry the card and to show their current and future healthcare providers in case of need for MRI scans.



MRI Safety Information inlexzo™ (gemcitabine intravesical system) 225 mg Patient Name _____ Healthcare Provider _____ Insertion Date _____ Other _____ Please carry this card at all times and show it to medical personnel who may be treating you.	MR Conditional USA - 787314 This patient has INLEXZO™ (gemcitabine intravesical system) inserted in the bladder and can safely undergo an MR exam only under very specific conditions. Scanning under different conditions may result in injury. Full MRI safety information is available in the MRI Safety Information section of the Instructions for Use of INLEXZO which can be obtained by calling 1-800-526-7736. Janssen Biotech, Inc. Horsham, PA 19044, USA Johnson & Johnson  close-up view Metal Wire
---	---

Cut the card along the **solid black line**, then fold it in half along the **black dashed line**



INLEXZO contains a metal wire. Inform patients that INLEXZO can only be safely scanned with MRI under specific conditions (See MRI Safety Information in the Prescribing Information).



Instruct patients who will have an MRI to tell their healthcare provider that they have INLEXZO.

INDICATION

INLEXZO™ (gemcitabine intravesical system) is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma *in situ* (CIS), with or without papillary tumors.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

INLEXZO™ is contraindicated in patients with:

- Perforation of the bladder.
- Prior hypersensitivity reactions to gemcitabine or any component of the product.

WARNINGS AND PRECAUTIONS

Risks in Patients with Perforated Bladder

INLEXZO™ may lead to systemic exposure to gemcitabine and to severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised.

Evaluate the bladder before the intravesical administration of INLEXZO™ and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.

Please read additional Important Safety Information on the next page.

Please read full [Prescribing Information](#) and [Instructions for Use](#) for INLEXZO.



Once you have made the clinical decision to prescribe INLEXZO, Johnson & Johnson has resources to help you support your patients.

J&J withMe is your single source for access, affordability, and treatment support programs from Johnson & Johnson.
Your patients will be connected to INLEXZO withMe.

Get started with J&J withMe
Visit Portal.JNJwithMe.com

Questions? Call 833-JNJ-wMe1 (833-565-9631),
Monday through Friday, 8:00 AM to 8:00 PM ET.

Visit JNJwithMe.com/hcp/Inlexzo for access and affordability information.

The patient support and resources provided by J&J withMe are not intended to give medical advice, replace a treatment plan from the patient's healthcare provider, offer services that would normally be performed by the provider's office, or serve as a reason to prescribe INLEXZO.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk of Metastatic Bladder Cancer with Delayed Cystectomy

Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. The risk of developing muscle invasive or metastatic bladder cancer increases the longer cystectomy is delayed in the presence of persisting CIS.

Of the 83 evaluable patients with BCG-unresponsive CIS treated with INLEXZO™ in Cohort 2 of SunRISe-1, 7 patients (8%) progressed to muscle invasive (T2 or greater) bladder cancer. Three patients (3.5%) had progression determined at the time of cystectomy. The median time between determination of persistent or recurrent CIS or T1 and progression to muscle invasive disease was 94 days.

Magnetic Resonance Imaging (MRI) Safety

INLEXZO™ can only be safely scanned with MRI under certain conditions. Refer to section 5.3 of the USPI for details on conditions.

Embryo-Fetal Toxicity

Based on animal data and its mechanism of action, INLEXZO™ can cause fetal harm when administered to a pregnant woman if systemic exposure occurs. In animal reproduction studies, systemic administration of gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after final removal of INLEXZO™. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after final removal of INLEXZO™.

Please read additional Important Safety Information on the next page.
Please read full [Prescribing Information](#) and [Instructions for Use](#) for INLEXZO.



IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS

Serious adverse reactions occurred in 24% of patients receiving INLEXZO™. Serious adverse reactions that occurred in >2% of patients included urinary tract infection, hematuria, pneumonia, and urinary tract pain. Fatal adverse reactions occurred in 1.2% of patients who received INLEXZO™, including cognitive disorder.

The most common (>15%) adverse reactions, including laboratory abnormalities, were urinary frequency, urinary tract infection, dysuria, micturition urgency, decreased hemoglobin, increased lipase, urinary tract pain, decreased lymphocytes, hematuria, increased creatinine, increased potassium, increased AST, decreased sodium, bladder irritation, and increased ALT.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no available data on the use of INLEXZO™ in pregnant women to inform a drug-associated risk.

Please see Embryo-Fetal Toxicity for risk information related to pregnancy.

Lactation

Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 week after final removal of INLEXZO™.

Females and Males of Reproductive Potential

Pregnancy Testing - Verify pregnancy status in females of reproductive potential prior to initiating INLEXZO™.

Contraception - Please see Embryo-Fetal Toxicity for information regarding contraception.

Infertility (Males) - Based on animal studies, INLEXZO™ may impair fertility in males of reproductive potential. It is not known whether these effects on fertility are reversible.

Geriatric Use

Of the patients given INLEXZO™ monotherapy in Cohort 2 of SunRISe-1, 72% were 65 years of age or older and 34% were 75 years or older. There were insufficient numbers of patients <65 years of age to determine if these patients respond differently to patients 65 years of age and older.

Please read full [Prescribing Information](#) and [Instructions for Use](#) for INLEXZO™.

cp-520096v1